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Neutrophil chemotaxis plays an essential role in innate immunity,
but the underlying cellular mechanism is still not fully character-
ized. Here, using a small-molecule functional screening, we
identiﬁed NADPH oxidase–dependent reactive oxygen species as
key regulators of neutrophil chemotactic migration. Neutrophils
with pharmacologically inhibited oxidase, or isolated from chronic
granulomatous disease (CGD) patients and mice, formed more fre-
quent multiple pseudopodia and lost their directionality as they
migrated up a chemoattractant concentration gradient. Knocking
down NADPH oxidase in differentiated neutrophil-like HL60 cells
also led to defective chemotaxis. Consistent with the in vitro
results, adoptively transferred CGD murine neutrophils showed
impaired in vivo recruitment to sites of inﬂammation. Together,
these results present a physiological role for reactive oxygen spe-
cies in regulating neutrophil functions and shed light on the
pathogenesis of CGD.
chronic granulomatous disease | innate immunity | NADPH oxidase
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eutrophils are major players in innate immunity and con-
stitute the ﬁrst line of host defense against invading bacteria
and other pathogens. In response to inﬂammatory stimuli, neu-
trophils migrate from the blood to infected tissues, where they
protect their host by engulﬁng, killing, and digesting invading
bacterial and fungal pathogens. Conversely, excessive neutrophil
accumulation can be detrimental to the system. Hence, neu-
trophil recruitment in response to inﬂammatory stimuli needs to
be well controlled.
Neutrophils are recruited to the site of infection by responding
to a variety of chemokines, leukotrienes, complement peptides,
and some chemicals released by bacteria directly, such as peptides
bearing the N-formyl group (i.e., formyl-peptides). Neutrophil
chemotaxis is mediated by heterotrimeric guanine nucleotide-
binding regulatory proteins (G protein)–coupled receptors
(GPCRs). One essential downstream target of GPCR is PtdIns
(3,4,5)P3.Chemoattractantsbindreceptorsoncellmembraneand
induce the dissociation of a speciﬁc G protein into α- and
βγ-subunits. Released βγ-subunits initiate accumulation of PtdIns
(3,4,5)P3 and subsequent actin polymerization at the leading edge
of chemotaxing cells. Earlier studies have suggested that PtdIns
(3,4,5)P3 plays the essential role of a cellular compass, localizing
to the leading edge of pseudopodia, mediating direction sensing
during chemotactic migration and cell polarity (1–4). However,
several recent studies have shown that loss of PI3K and reduced
PtdIns(3,4,5)P3 level lead to decreased polarity, but does not
affect the ability of the cell to sense chemoattractant gradients. In
both human neutrophils (5, 6) and Dictyostelium (7–9), chemo-
taxis could occur independently of the PI3K-dependent actin
polymerization, although it was somewhat delayed, suggesting
extra pathways are required for neutrophil chemotaxis.
To identify these putative signal-induced chemotactic path-
ways, we conducted a functional screening for chemical com-
pounds that disrupt neutrophil directionality. We have identiﬁed
NADPHoxidasedependent reactive oxygenspecies(ROS) askey
regulators of neutrophil chemotaxis. Neutrophils with pharma-
cologically inhibited NADPH oxidase, or isolated from chronic
granulomatous disease (CGD) patients and mice, displayed more
frequent multiple pseudopodia formation and impaired direc-
tionality during chemotaxis. This ﬁnding provides a cellular
mechanismforCGDpathogenesisandmightleadtodevelopment
of new therapeutic strategies for this disease.
Results
Screening for Inhibitors of Neutrophil Chemotaxis. The screening
was performed using an EZ-TAXIScan chemotaxis device in
which a stable chemoattractant gradient was formed in a 260-
μm–wide channel (Fig. S1A). Freshly puriﬁed human primary
neutrophils migrated robustly up the gradient and most cells
crossed the channel in 20 min (Fig. S1B). A Tocris screening
library containing 386 biologically active compounds was used
for screening (Table S1). To achieve the maximal inhibition of
each targeted pathway in the primary screening, we treated
neutrophils with each drug at a concentration equivalent to 10
times the IC50 of the drug. Although most compounds did not
affect neutrophil chemotaxis (Dataset S1), 83 compounds dis-
played inhibitory effects. (The video ﬁles for each compound will
be released to a public database after the publication of this
article.) The inhibitory effects were elicited via a variety of
mechanisms (Table S1), such as induction of cell death (Dataset
S2), complete inhibition of polarization and migration, slow
migration, and impairment of directionality. Selected com-
pounds from the primary screen were then used at 0.2 to 10 times
the IC50 in a secondary screening (Dataset S3). Most positive
compounds identiﬁed from the primary screening showed the
same inhibitory effect at lower concentrations, suggesting that
the drug-induced phenotype changes were most likely caused by
speciﬁc inhibition of each targeted pathway.
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tionality,butdidnotinhibitneutrophilmigrationcompletely(Figs.
S2 and S3). Five of these drugs are compounds that inhibit
microtubule polymerization, which is consistent with recent
reports indicating that microtubules negatively regulate uropod
signaling and enhance directional sensing in neutrophils (10, 11).
Interestingly, the most dramatic inhibitory effect was induced by
diphenyleneiodonium chloride (DPI), a well characterized and
commonly used ﬂavoprotein inhibitor that was known to suppress
activity of NADPH oxidase and NOS (12–14). As neutrophil
chemotaxis was not affected by other NOS inhibitors (e.g.,
7-nitroindazole, L-NIO dihydrochloride, 1-[2-(triﬂuoromethyl)
phenyl]imidazole, 2-amino-5,6-dihydro-6-methyl-4H-1,3 thiazine,
ethylisothiourea, S-isopropylisothiourea hydrobromide, NG-
methyl-L-arginine, nω-nitro-l-arginine methyl ester, nω-nitro-L-
arginine, and L-canavanine) or NO donors (3-morpholinosydno-
nimine, s-nitrosoglutathione, and spermine NONOate; Dataset
S1), it is most likely that the effect of DPI on neutrophil chemo-
taxis was mediated by the inhibition of NADPH oxidase, sug-
gestingthatchemoattractantelicitedROSproductionmightplaya
role in regulating neutrophil chemotactic migration.
ROSArePhysiologicalRegulatorsofNeutrophilChemotacticMigration.
We further investigated the effect of DPI on neutrophil direc-
tional migration using a transwell migration system. Cells were
plated on transwell ﬁlters and induced to migrate in response to
Fig. 1. Pharmacological inhibition of NADPH oxidase–mediated ROS production in human neutrophils leads to more frequent formation of multiple pseu-
dopodiaandreducedchemotaxisefﬁciency.(A)InhibitionofNADPH oxidasedecreasestranswellmigrationofhumanneutrophils. Humanneutrophilswereleft
untreated or pretreated with 50 μM DPI for 30 min at 37 °C, andthen allowed to migrate in response to the indicated concentration of fMLP. Percentage of cells
that migrated into the bottom well was recorded. Data shown are means ± SD from n = 3 wells, from one experiment representative of three. (*P < 0.05 vs.
untreated neutrophils.) (B) Chemotaxing NADPH oxidase–inhibited human neutrophils display multiple pseudopodia more frequently, but do not show dif-
ferenceincellspeed.Representative imagesofhumanneutrophilstreated(Right)ornottreated(Left)with50μMDPIandallowedtochemotaxinresponsetoa
chemoattractant gradient generated by addition of 1 μL of 100 nM fMLP in the EZ-TAXIScan device. White arrowheads specify pseudopodia in the cells.
Percentage of cells that display multiple pseudopodia (bottom left, n = 20 cells; Fisher 2 × 2 test, *P < 0.05 vs. untreated) and migration speed (bottom right,
mean ± SD from n = 20 cells; Student t test, *P > 0.05 vs. untreated) during the course of the EZ-TAXIScan chemotaxis assay in the DPI-treated or untreated case
were quantiﬁed as described in Experimental Procedures.( C) Inhibition of NADPH oxidase leads to multiple pseudopod formation and defective directionality
in fMLP-, LTB4-, and IL-8–mediated chemotaxis. Neutrophil chemotaxis in response to addition of 100 nM fMLP, 100 nM LTB4, or 10 nM IL-8 (1 μL each), with 50
μM DPI treatment (or without treatment), was analyzed (n = 20 cells) for directionality, upward directionality, and percentage of neutrophils displaying
multiple pseudopodia as described earlier (n = 20 cells, *P < 0.05). (D) Pharmacological agents that inhibit ROS production cause chemotaxis defect in human
neutrophils. fMLP-induced ROS production (Fig. S5 Top) in human neutrophils (5 × 10
5) pretreated with sinomenine (10 μM), DPI (50 μM), EHNA hydrochloride
(40 μM), or LE135 (14 μM), or without pretreatment, was evaluated by stimulating neutrophils with 100 nM fMLP and monitoring chemiluminescence (for 1 s)
every 7 s for 280 s, in the presence of 50 μM luminol and 0.8 U HRP in a luminometer at 37 °C. Data represent maximal chemiluminescence in drug-treated
neutrophils normalized to maximal chemiluminescence in untreated neutrophils (mean ± SD, n = 3 wells from one experiment representative of three). Drug-
treated (and untreated) neutrophils were also exposed to an fMLP gradient generated by addition of 100 nM fMLP (1 μL) in the EZ-TAXIScan device. Images and
cell tracks of migrating neutrophils were evaluated for directionality, upward directionality and percentage of neutrophils displaying multiple pseudopodia as
described earlier (n = 20 cells; *P < 0.05). (E)H 202 treatment of NADPH oxidase–inhibited human neutrophils rescues defect in pseudopod formation and
chemotaxis. Human neutrophils were pretreated with 50 μM DPI (or without) and then treated with (or without) 100 μMH 202 for 5 min and then allowed to
chemotax in response to a fMLP gradient in the EZ-TAXIScan device as described earlier. Migrating neutrophils were evaluated (n = 20 cells; *P < 0.05 vs. DPI-
treated neutrophils) for directionality, upward directionality, and percentage of neutrophils displaying multiple pseudopodia as described earlier.
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of neutrophils to these lower wells requires 2D chemotaxis on top
of the ﬁlter (toward the holes), followed by migration through the
holes into the bottom well of chemoattractant. The number of
cells in the bottom well was then used to calculate percentage of
cells migrated. Consistent with the EZ-TAXIScan results, treat-
ment with DPI signiﬁcantly inhibited neutrophil migration into
the lower wells (Fig. 1A). To take a closer look at the morpho-
logical changes elicited by DPI treatment, multiple pseudopod
formation was measured in chemotaxing neutrophils. We
observed that DPI-treated neutrophils showed multiple pseudo-
podia much more frequently compared with untreated neu-
trophils, although the migration speed of these two populations
was essentially the same (Fig. 1B). The DPI-induced inhibitory
effect appeared not to be speciﬁc to chemotaxis-elicited by che-
moattractant N-formyl-methionyl-leucyl-phenylalanine (fMLP),
which was used for the initial screening. Treatment with DPI also
signiﬁcantly inhibited chemotaxis elicited by leukotriene B4
(LTB4) and IL-8, suggesting that DPI might block a general
pathway in directional migration (Fig. 1C). Interestingly, IL-8–
mediated chemotaxis was more resistant to DPI treatment com-
pared with fMLP and LTB4. It seems that this is not a sensitivity
Fig. 2. Disruption of NADPH oxidase leads to chemotaxis defects. (A–E) Neutrophils from CGD mice do not produce ROS in response to chemoattractant
stimulation, display multiple pseudopodia, and show loss of directionality during chemotaxis. (A) ROS production in neutrophils (5 × 10
5) from WT or CGD
mice after stimulation with 1 μM fMLP was evaluated by monitoring chemiluminescence (for 1 s) every 7 s for 280 s, in the presence of 50 μM luminol and 0.8 U
HRP in a luminometer at 37 °C. Data represents mean ± SD from three wells from one experiment representative of three. (B) Neutrophils from WT and CGD
mice (3,000 cells) were plated into the EZ-TAXIScan device and exposed to a shallow chemoattractant gradient generated by addition of 1 μL LTB4 (100 nM).
Cell tracks of migrating WT (Left) and CGD (Right) neutrophils (cells that move ≥65 μm from the bottom of the channel; n = 20) were traced from captured
images, realigned such that all cells started from the same starting point (0,0) and plotted. Chemoattractant concentration increases in the positive y
direction. (C) Representative images of WT (Left) and CGD migrating neutrophils (Right) are also shown; white arrowheads specify pseudopodia. (D)
Migrating neutrophils were evaluated (n = 20 cells; *P < 0.05 vs. WT neutrophils) for directionality, upward directionality, percentage of neutrophils dis-
playing multiple pseudopodia, and migration speed as described earlier. (E) Transwell migration of CGD mice neutrophils. WT or CGD murine neutrophils
were allowed to migrate in response to the indicated concentration of LTB4. Percentage of cells that migrated into the bottom well was recorded. Data
shown are means ± SD from three wells from one experiment representative of three. (*P < 0.05 vs. WT neutrophils.) (F–H) Knocking down p22phox via siRNA
results in impaired cell migration and chemotaxis. HL60 cells were differentiated with 1.75% DMSO for 1 d, transfected with 1 μM control siRNA or p22phox
siRNA, and further differentiated until d 5 or 6. (F) Knockdown of p22phox in dHL60 cells. At d 5 (Left)o rd6( Right), dHL60 cells were lysed and probed with
p22phox antibody to evaluate knockdown and GAPDH antibody to evaluate loading. (G) Decreased ROS production in p22phox-knockdown dHL60 cells. ROS
production in control siRNA or p22phox siRNA transfected dHL60 cells (2 × 10
5, 5 d of differentiation) after stimulation with 10 nM C5a was evaluated by
monitoring chemiluminescence (for 1 s) every 30 s for 300 s, in the presence of 50 μM luminol and 0.8 U HRP in a luminometer at 37 °C. (H) Control siRNA or
p22phox siRNA transfected dHL60 cells (d 5) were exposed to a chemoattractant gradient generated by addition of 25 nM or 100 nM C5a (1 μL) in the EZ-
TAXIScan device and imaged every 0.5 min for 20 min. Cell tracks of migrating dHL60 cells (n = 15) were traced from the captured images, realigned to start
from the same point (0,0), and plotted (Left). Migration paths of the dHL60 cells were evaluated for a 0- to 20-min time frame (n > 15 cells, *P < 0.005 vs.
control siRNA dHL60 cells) for directionality, upward directionality, and migration speed as described in Experimental Procedures (Right).
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the effect of DPI treatment on IL-8–induced chemotaxis is always
weaker (Fig. S4). This effect might be caused by relatively lower
ROS production in IL-8–treated cells. Chemical inhibitors often
have multiple targets. DPI may also inhibit other ﬂavin-
containing enzymes. To ensure that the DPI-induced neutrophil
chemotaxis defect was indeed caused by inhibition of NADPH
oxidase, we examined another NADPH oxidase inhibitor, sino-
menine (15). Similar to DPI, sinomenine induced multiple
pseudopodia in chemotaxing neutrophils and signiﬁcantly
reduced chemotaxis efﬁciency. Interestingly, two of the com-
pounds identiﬁed from the initial screening, EHNA hydro-
chloride and LE135, previously known as adenosine deaminase
inhibitor and retinoic acid antagonist, respectively, also drastically
suppressed chemoattractant-elicited NADPH oxidase activation,
again indicating the involvement of ROS in chemotactic migra-
tion (Fig. 1D and Fig. S5). Further supporting this hypothesis is
the observation that DPI-induced chemotaxis defects were par-
tially rescued by including H2O2 in chemotaxis buffer (Fig. 1E).
NADPH Oxidase Is Required for Efﬁcient Neutrophil Chemotaxis.
Although DPI is a well known and commonly used NADPH oxi-
dase, its effect on cell migration may be mediated by other unde-
ﬁned mechanisms. To deﬁnitely prove that the DPI-induced
neutrophil chemotaxis defect is at least partially caused by inhib-
ition of NADPH oxidase, we next explored neutrophil chemotaxis
using a CGD mouse in which gp91 subunit of NADPH oxidase
holoenzyme was deleted and thus chemoattractant-elicited super-
oxide production was completely abolished (Fig. 2A). Similar to
chemicalinhibition,neutrophilsisolatedfromthesemicedisplayed
multiple pseudopods (Fig. 2C) and reduced chemotaxis efﬁciency
(Fig. 2 B and D). Consistently, neutrophils isolated from the CGD
mice also displayed a migration defect in the transwell assay com-
pared with WT neutrophils (Fig. 2E). Finally, we investigated the
chemotaxis of neutrophil-like differential HL60 cells in which the
p22
phox subunitofNADPHoxidasewasknockeddownbyaspeciﬁc
siRNA,andessentiallythesameresultswereobserved(Fig.2F–H).
Collectively, all these results suggest that signal-induced NADPH
oxidase-mediated ROS production plays an essential role in regu-
lating neutrophil chemotaxis.
Neutrophils Isolated from CGD Patients Also Show Severe Chemotaxis
Defect. To further explore the physiological and clinical sig-
niﬁcance of the regulation of neutrophil migration by ROS, we
examined chemotaxis behaviors of neutrophils isolated from a
CGD patient that contain mutated alleles of the gene encoding
gp91
phox. As expected, neutrophils from the CGD patient dis-
played impaired chemoattractant-elicited ROS production in
comparison with neutrophils from a healthy volunteer (Fig. 3A).
The ROS peak in these neutrophils is signiﬁcant, but is much
smaller than that in the WT neutrophils. Adhesion-induced ROS
production in the absence of chemoattractant was also abolished
in the CGD neutrophils. The CGD neutrophils displayed a
striking chemotaxis defect, showing lack of directionality, more
frequent formation of multiple pseudopodia, and slow migration
toward the direction of higher chemoattractant (Fig. 3B). It is
noteworthy that the CGD patient in this study was receiving
IFN-γ treatment. Nevertheless, it is unlikely that the observed
neutrophil chemotaxis defect was a result of this treatment, as
IFN-γ–treated WT neutrophils showed normal directionality
during chemotaxis. Collectively, these results suggest that the
defective neutrophil chemotaxis might be contributive to the
compromised bactericidal activity in CGD patients, providing a
cellular mechanism for CGD pathogenesis.
CGD Mice Display Impaired in Vivo Neutrophil Recruitment. Our in
vitroexperimentsshowedthatneutrophilsdepletedofROSdisplay
reduced chemotaxis efﬁciency. We next investigated whether this
defectinchemotaxiswillleadtoimpairedneutrophilrecruitmentto
sites of inﬂammation in live mice using a murine acute peritoneal
inﬂammation (i.e., peritonitis) model. To compare neutrophil
recruitment under exactly the same environment, an adoptive
transfer experiment was conducted (Fig. S6). We labeled in vitro
puriﬁedCGDneutrophilswithintracellularﬂuorescentdye5-(and
6-) carboxyﬂuorescein diacetate succinimidylesters (CFSE; green)
and WT neutrophils with another dye, 5- (and 6-) chloromethyl
SNARF-1 acetate (red), or vice versa. The mixed (1:1) population
was i.v. injected into a WT recipient mouse 2.5 h after the i.p. thi-
oglycolate (TG) injection. By doing this, variability caused by dif-
ference in inﬂammatory environment in each individual recipient
mouse will be eliminated. CGD (green) and WT (red) neutrophils
Fig. 3. Neutrophils isolated from the CGD patient are defective in ROS
production and chemotactic migration. (A) Decreased ROS production in
neutrophils from a CGD patient. ROS production in neutrophils (5 × 10
5)
from a CGD patient or a healthy volunteer after addition of HBSS (Top)o r
100 nM fMLP (Bottom) was evaluated by monitoring chemiluminescence
(for 1 s) every 20 s for 360 s, in the presence of 50 μM isoluminol and 0.8 U
HRP in a luminometer at 37 °C. Data represent mean ± SD from three wells.
(B) Neutrophils from the CGD patient or healthy volunteer were exposed to
a chemoattractant gradient generated by addition of 100 nM fMLP (1 μL) in
the EZ-TAXIScan device and imaged every 0.5 min for 20 min. Cell tracks of
migrating neutrophils (n = 20) were traced from the captured images,
realigned to start from the same point (0,0), and plotted (Top). Images of
chemotaxing neutrophils from the CGD patient or healthy volunteer
are shown (Middle). White arrowheads specify pseudopodia in the cells.
Neutrophils were evaluated (n =2 0c e l l s ,* P < 0.01 vs. WT neutrophils) for
directionality, upward directionality, percentage of neutrophils displaying
multiple pseudopodia, and migration speed as described earlier (Bottom).
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neutrophil numbers at 4 h after the TG injection, when neutrophil
death is minimal, the ratio of CGD neutrophils to WT neutrophils
most likely reﬂected their relative capability to migrate to the
inﬂamed peritoneal cavity. Consistent with the in vitro results, we
detected a much reduced peritoneal recruitment of CGD neu-
trophils compared with WT neutrophils (Fig. 4A). A similar effect
wasalsodetectedinamurineairpouchmodelinwhichrecruitment
ofadoptively transferredneutrophils to a preformed air pouchwas
induced by TNF-α (Fig. 4B). These results further support the
conclusion that ROS generated by NADPH oxidase are key phys-
iological regulators of actin dynamics in neutrophils.
Discussion
In this study, using an unbiased screening approach, we have
identiﬁed ROSs as essential players for modulating neutrophil
chemotaxis. Chemotaxis is a process in which cells sense and
move up a gradient of molecules (chemoattractants). It plays a
central role in the regulation of host defense and inﬂammatory
reactions by recruiting circulating effector leukocytes, including
neutrophils, monocytes, and effector T cells, to the sites of injury
or infection. During chemotaxis, chemoattractants elicit a num-
ber of changes in neutrophils. These include a localized poly-
merization of F-actin at the site of cell cortex closest to the
chemoattractant source, a morphological change characterized
by cell elongation, the formation of new lamellipodia or pseu-
dopods at the leading edge, and the forward protrusion of the
leading edge followed by retraction of posterior of the cell. We
have found that neutrophils with inhibited ROS production that
were isolated from CGD patients or mice or pharmacologically/
siRNA–treated to inhibit the NADPH oxidase complex dis-
played defective migration. These neutrophils formed more
frequent multiple pseudopodia and lost their directionality as
they migrated up a chemoattractant concentration gradient.
CGD is an inherited disorder characterized by recurrent bouts
of infection as well as chronic inﬂammation with granuloma
formation. Consistently, neutrophil recruitment to sites of
inﬂammation is dramatically elevated in the CGD mice (16).
This hyperinﬂammatory phenotype is likely caused by dysfunc-
tional kynurenine pathway of tryptophan catabolism (17) and
suppression of ROS-induced deactivation of proinﬂammatory
chemokines such as C5a, fMLP (18), LTB4 (19), and IL8 (20).
At the sites of infection, the inability of CGD neutrophils to
produce ROS in response to chemoattractant stimulation may
contribute to the impaired bactericidal activity of these cells. Our
discovery that depletion of signal-elicited ROS production in fact
inhibits neutrophil chemotactic migration provides another cel-
lular mechanism for CGD pathogenesis and might lead to
development of new therapeutic strategies for this disease.
How is chemotactic migration regulated by ROSs? ROSs have
been identiﬁed as important second messengers that can regulate
intracellular signal transduction under a variety of physiological
and pathophysiological conditions. This has been shown to occur
predominantly via oxidation of thiols (-SH) on protein cysteine
Fig. 4. CGD neutrophils exhibit an intrinsic defect in recruitment to sites of inﬂammation. (A) Recruitment of adoptively transferred neutrophils in the TG-
induced peritonitis model. Neutrophils isolated from WT and CGD mice were labeled with intracellular ﬂuorescent dye CFSE (ﬁnal concentration, 1 μM;
Molecular Probes) or 5- (and 6-) chloromethyl SNARF-1 acetate (ﬁnal concentration, 1 μM; Molecular Probes) at 37 °C for 10 min. Labeled cells were mixed (1:1)
as indicated and then injected i.v. (via tail vein) into WT mice that have been challenged with 1 mL 3% TG for 2.5 h. Peritoneal ﬂuids were harvested 1.5 h
after the injection of cell mixture. The amount of adoptively transferred neutrophils recruited to the peritoneal cavity was analyzed using a BD FACSCanto II
ﬂow cytometer (Becton Dickinson) and BD FACSDiva software. Relative recruitment of neutrophil was calculated as the ratio of indicated populations int h e
peritoneal cavity. (B) Recruitment of adoptively transferred neutrophils to a preformed air pouch. The dorsal air pouch was generated on WT recipient mice as
described in Experimental Procedures. Neutrophil recruitment to the pouch was induced by TNF-α, which was directly injected into the pouch 2.5 h before the
neutrophil injection. The pouch was ﬂushed 1.5 h after the injection of cell mixture. The relative recruitment of WT and CGD neutrophil was calculated as
described earlier.
3550 | www.pnas.org/cgi/doi/10.1073/pnas.0914351107 Hattori et al.residues, resulting in reversible protein posttranslational mod-
iﬁcations such as glutathionylation, disulﬁde bond formation,
and sulfenic acid formation. Many of these modiﬁcations control
signal transduction by altering functionality/activity of the pro-
tein involved. Redox regulation of numerous proteins such as
Ras, protein tyrosine kinases (Src kinases), and protein tyrosine
phosphatases have been reported and are known to alter protein
functions. PTEN has also been identiﬁed as a target of ROSs
(21–23). ROSs can also directly regulate actin polymerization via
modifying G-actin monomers (21–23). In addition, the NADPH
oxidase is also essential for chemoattractant-elicited depolari-
zation of membrane potential and can regulate Ca
2+,K
+
homeostasis in neutrophils (24). This may contribute to direc-
tional sensing in an indirect way. The exact mechanism by which
ROS regulate neutrophil chemotaxis needs to be further inves-
tigated. During chemotaxis, many signaling events take place
locally within the cell. For example, Rac-related signaling and
actin polymerization are detected at the leading edge of che-
motaxing cells, whereas RhoA activation and contractile actin–
myosin complexes appear only at the back of the cells. Inter-
estingly, we found NADPH oxidase was highly enriched near the
leading edge of migrating neutrophils (Fig. S7). Whether this
speciﬁc localization is essential for chemotaxis needs to be
further investigated.
Experimental Procedures
Neutrophil Puriﬁcation and Functional Assays. Human blood neutrophil
puriﬁcation, murine bone marrow neutrophil puriﬁcation, quantiﬁcation of
F-actin levels by phalloidin labeling, measurement of superoxide production
by luminol chemiluminescence, micropipette chemotaxis, and transwell
migration assays were performed as described previously (25–27). Peripheral
blood was obtained from a human CGD patient and healthy volunteer, with
informed consent. EZ-TAXIScan chemotaxis assay, analysis of cell tracks and
morphology, siRNA knockdown, and other related assays are described in SI
Materials and Methods.
Recruitment of Adoptively Transferred Neutrophils in TG-Induced Peritonitis.
Peritonitis was induced as previously described (26). Neutrophils isolated
from WT and CGD mice were labeled with intracellular ﬂuorescent dye CFSE
(ﬁnal concentration, 1 μM; Molecular Probes) or 5- (and 6-) chloromethyl
SNARF-1 acetate (ﬁnal concentration, 1 μM; Molecular Probes) at 37 °C for 10
min. Labeled cells were mixed as indicated in Fig. S6 then injected i.v. (via tail
vein) into WT mice that have been challenged with 1 mL 3% TG for 2.5 h.
Mice were euthanized by CO2 inhalation 1.5 h after the injection of cell
mixture (4 h after TG injection) and peritoneal exudate cells were recovered
by peritoneal lavage with 10 mL of ice-cold PBS solution containing 5 mM
EDTA. The amount of adoptively transferred neutrophils recruited to the
peritoneal cavity was analyzed using a BD FACSCanto II ﬂow cytometer
(Becton Dickinson) and BD FACSDiva software. Relative recruitment of
neutrophil was calculated as the ratio of indicated populations in the
peritoneal cavity.
Recruitment of Adoptively Transferred Neutrophils in a Murine Dorsal Air
Pouch Model. A dorsal air pouch was created by injecting mice with 5 mL of air
s.c. on the back at d 0. On d 3 and 5, the pouches were reinﬂated with 2 mL of
air. At 6 d after the initial air injection, TNF-α (in 0.5 mL sterile 0.9% saline
solution) was directly injected into the pouch. Four hours after TNF-α injec-
tion, mice were anesthetized, and the pouch was ﬂushed with 2 mL saline
solution. The relative recruitment of WT and CGD neutrophils was calculated
as described earlier.
Statistics. Analysis of statistical signiﬁcance for indicated data sets was per-
formed using the Student t test capability on Microsoft Excel.
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SI Methods
Analysis of Cell Tracks and Morphology. (x,y) coordinates of mi-
grating neutrophils (i.e., neutrophils that cross >65 μm from the
starting line) were tracked from sequential images using DIAS
imaging software (Solltech). Cell tracks were then realigned such
that all of the cells started from the same starting point (0,0) and
plotted using Matlab. Migration parameters are described in
detail in Fig. S3. Directionality and upward directionality were
calculated as the straight-line migration distance from the origin
divided by total migration length and straight-line distance mi-
grated in the upward direction divided by total migration length
(Fig. S3). Migration speed (in μm/min) was calculated as average
of cell speeds (migration distance between the current frame and
the previous frame divided by the time between sequential
frames, 0.5 min) at each captured frame. All parameters were
calculated only for migrating cells in the 5 min to 15 min time
frame of each movie. Percentage of neutrophils with multiple
pseudopodia during the course of the 20-min video was eval-
uated from images of migrating cells. Fisher exact test (2 × 2)
was performed to evaluate signiﬁcant difference from untreated
or WT neutrophils.
EZ-TAXIScan Chemotaxis Assay. The EZ-TAXIScan chamber
(Effector Cell Institute) was assembled with a 260-μm-wide × 4-
μm-thick silicon chip on a 2-mm untreated glass base, as de-
scribed by the manufacturer and ﬁlled with RPMI/0.1% BSA.
Inhibitor-treated (or carrier-treated) neutrophils (1 μL, 3 × 10
6/
mL) were added to the lower reservoir of each of the six chan-
nels and allowed to line up by removing 18 μL of buffer from the
upper reservoir. RPMI/0.1% BSA (15 μL with the appropriate
pharmacological inhibitor) was then added to ﬁll both reservoirs
to the brim. One microliter of chemoattractant (fMLP, C5a, or
LTB4) was then added to the upper reservoir and neutrophil
migration (at 37 °C) in each of the channels was captured se-
quentially every 30 s for 20 min using a 10× lens on a Discovery
Screening System (Universal Imaging). Pharmacological in-
hibitors (from Tocris Bioscience library) along with 200 nM of
pan-PI3K inhibitor wortmannin (used to reduce random migra-
tion) were added directly to human neutrophils (100 μL, 3 × 10
6/
mL) in RPMI/0.1% BSA and incubated in a 37 °C, 5% CO2
chamber for 30 min before the chemotaxis assay.
CGD Mice. X-linked CGD mice (1) that contain disrupted alleles
of the gene encoding gp91
phox (B6.129S6-Cybbtm1Din/J; strain,
C57BL/6) were purchased from Jackson Laboratories. In all of
the experiments performed with the CDG mice, we used C57BL/
6 mice of the same age as WT controls. All procedures involving
mice were approved and monitored by the Animal Care and Use
Committee of Children’s Hospital Boston.
Knockdown of p22
phox A predesigned duplexed Stealth siRNA
(Invitrogen) that targets p22
phox (CYBA gene; accession no.,
NM_000101.2) was used to knock down p22
phox in dHL60 cells
(sensesequence,ACUAUGUUCGGGCCGUCCUGCAUCU;
antisense sequence, AGA UGC AGG ACG GCC CGA ACA
UAG U). The negative control used was an ON-TARGETplus
nontargeting siRNA 2 (Dharmacon). For gene silencing HL60
cellsweredifferentiatedfor1dwith1.75%DMSO.Ond1,2×10
6
cells were resuspended in 100 μL Cell Line V nucleofector sol-
ution, mixed with 1 μM siRNA (negative control or p22
phox), and
nucelofected using the T-019 program as per manufacturer in-
structions.Cellswerethenculturedin2mLIMDMplus20%FBS
plus 1.75% DMSO for 4 to 5 d, and then harvested for Western
blotting, ROS production, and chemotaxis assays. Lysates of dif-
ferentiatedHL60cellswereprobedforp22
phoxexpressionusingan
anti-rabbit p22
phox antibody (Santa Cruz Biotechnology) and
loading was evaluated using a GAPDH antibody (Encor Bio-
technology). ROS production assays and EZ-TAXIScan chemo-
taxis assays were performed as described earlier.
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Hattori et al. www.pnas.org/cgi/content/short/0914351107 1o f7Fig. S1. Screening for pharmacological agents that modulate actin dynamics during neutrophil chemotaxis. (A) Cross-sectional schematic view of one of the
six channels in EZ-TAXIScan device. The apparatus consists of a six-channel silicon chip (with two holes for each channel) pressed on top of a glass surface using
a rubber gasket and metal holder. Cells (1 μL) are loaded to the bottom of one reservoir and chemoattractant (1 μL) is added to the other reservoir. This sets up
a chemoattractant gradient between the reservoirs, driving cells to migrate toward the chemoattractant reservoir through a narrow gap (4 μm height, 260 μm
length) between the silicon chip and glass surface. Images of migrating cells in each of the six channels are captured in parallel using a 10× lens coupled to a
CCD camera. (B) Chemotaxis of human neutrophils in response to chemoattractant fMLP. Human neutrophils (3,000 cells) were plated into the neutrophil
reservoir (bottom well) of the EZ-TAXIScan device and exposed to no chemoattractant (Left) or to a chemoattractant gradient (Right) generated by addition of
100 nM fMLP (1 μL) into the chemoattractant reservoir (top well). Images of neutrophils are shown at 0 min, 10 min, and 20 min after chemoattractant
addition.
Hattori et al. www.pnas.org/cgi/content/short/0914351107 2o f7Fig. S2. Biologically active pharmacological agents that decrease chemotaxis efﬁciency of human neutrophils. Neutrophils were incubated at 37 °C for 30 min
without any treatment or with the following pharmacological agents: 2,4-diamino-6-hydroxypyrimidine (DAHP; 300 μM), GF 109203X (58 μM), dibutyryl-cAMP
(1 mM), SKF 96365 hydrochloride (56 μM), nocodazole (16 μM), vinblastine sulfate (1.78 μM), DPI (100 μM), colchicine (10 μM), D-6413 (0.74 μM), EHNA hy-
drochloride (40 μM), 2-methoxyestradiol (19 μM), and LE 135 (14 μM). They were then exposed to a chemoattractant gradient generated by addition of 100 nM
fMLP (1 μL) in the EZ-TAXIScan device and imaged every 0.5 min for 20 min. (A) Cell tracks of untreated and drug treated migrating neutrophils (cells that move
≥65 μm from the bottom of the channel; n = 20) were traced from the captured images, realigned such that all cells started from the same starting point (0,0),
and plotted. Chemoattractant concentration increases in the positive y direction. (B and C) Cell tracks of migrating neutrophils in the 5 min to 15 min time
frame were analyzed as described in Experimental Procedures to determine directionality (0–1) (B), deﬁned as straight-line migration distance from the origin
divided by the total migration length; and upward directionality (−1t o1 )( C), deﬁned as straight-line distance migrated in the upward direction divided by
total migration length (Fig. S3). Data in B and C are represented as mean ± SD for 20 cells. (*P < 0.05 versus untreated neutrophils.)
Hattori et al. www.pnas.org/cgi/content/short/0914351107 3o f7Fig. S3. Chemotaxis parameters for neutrophil migration in response to a chemoattractant gradient. If n is the number of successive frames analyzed and (xn,
yn, tn) denotes the position of the neutrophil (xn, yn) at any time tn, the chemotaxis parameters can be calculated as follows: directionality (0–1) is dS / (d1 +
d2 ...+ df), speed (μm/min) is (d1 / (t1 − t0) + d2 / (t2 − t1) + ...+ df / (tf − t3)) / n, and upward directionality (−1t o1 )i sd U/( d 1+d 2...+ df). Here, “f” denotes
the ﬁnal position of the cell, ”0” denotes the initial position, dn is the distance migrated between two successive frames (xn, yn) and (xn-1, yn-1), dS is the
straight-line migration distance, i.e., distance between (x0, y0) and (xf, yf), and dU is the straight-line migration distance in the direction of the chemo-
attractant gradient (upward), i.e., distance between (x0, y0) and (x0, yf), yf-y0.
Fig. S4. Sensitivity to chemoattractant: Quantiﬁcation of rufﬂing response and pseudopod formation. Murine neutrophils (0.5 × 10
4 cells in 50 μL) were
pretreated with 30 μM DPI or not pretreated and then stimulated with 50 μLo f2 × concentrated fMLP (or not stimulated) for 4 min. Cells were then ﬁxed with
100 μL 4% formaldehyde in PBS solution, plated onto coverslips, and imaged. Percentage of neutrophils with rufﬂes or extended pseudopods were quantiﬁed
from the images (1). More than 100 neutrophils were evaluated for each data point. Data are mean ± SD from three stimulations, from one experiment
representative of three. (P > 0.05 vs. untreated.)
1. Subramanian KK, et al. (2007) Tumor suppressor PTEN is a physiologic suppressor of chemoattractant-mediated neutrophil functions. Blood 109:4028–4037.
Hattori et al. www.pnas.org/cgi/content/short/0914351107 4o f7Fig. S5. Chemoattractant induced ROS production is suppressed by speciﬁc pharmacological inhibitors (raw data for Fig. 1D in the main text). Human blood
neutrophils (5 × 10
5) were left untreated or treated with 40 μM EHNA hydrochloride (A), 14 μM LE 135 (B), 50 μM DPI (C), or 10 μM sinomenine (D) for 30 min at
37 °C. Cells were then stimulated with 100 nM fMLP, and ROS production was monitored in the presence of 50 μM luminol and 0.8 U of HRP in a luminometer
at 37 °C. Chemiluminescence (in arbitrary light units) was recorded (for 1 sec) at indicated time points. Data are mean ± SD (n = 3) from one experiment
representative of three. Assays for A–D were conducted on different days with blood neutrophils from different patients.
Hattori et al. www.pnas.org/cgi/content/short/0914351107 5o f7Fig. S6. Illustration of strategy used for adoptive transfer experiments. Bone marrow neutrophils from WT and CGD mice were labeled with different colors
(SNARF1- or CFSE-labeled), mixed 1:1 and then i.v. injected into WT recipient mice that have been challenged with TG (intraperitoneally injected) or TNF-α
(injected into an artiﬁcially generated dorsal air pouch). After 90 min, cells were collected from the peritoneal cavity or air pouch. The relative recruitment of
CGD and WT neutrophils in the WT recipient was evaluated by FACS analysis.
Fig. S7. NADPH oxidase is enriched near the leading edge of chemotaxing neutrophils. Puriﬁed human neutrophils were washed once with HBSS with calcium
and magnesium, and were plated onto glass coverslips coated with 10 μg/mL ﬁbronectin for 10 min at 37 °C. Neutrophils were then stimulated with 100 nM
fMLP for indicated time, ﬁxed with 6% paraformaldehyde/PBS solution for 5 min at room temperature, and washed three times with PBS solution. Neutrophils
were then permeabilized with 0.2% Triton-X in PBS solution for 10 min at room temperature and then preblocked with PBS solution/1% BSA blocking buffer
for 15 min at room temperature. Primary antibody (1:1,000; rabbit anti-p22 subunit of NADPH oxidase) was then added to the ﬁxed cells in the blocking buffer
for 1 h, washed three times with PBS solution, followed by incubation with secondary antibodies (1:1,000; Alexa 488–conjugated anti-rabbit IgG) for 30 min
and three washes with PBS solution. The distribution of p22 was imaged in the FITC channel.
Hattori et al. www.pnas.org/cgi/content/short/0914351107 6o f7Table S1. Summary of the primary screening
Drug effect No. of compound
No effect 303
Cell death (lysed cells) 15
Complete inhibition of polarization & migration (intact but round cells) 18
Slow and/or “long-tailed” migration 38
Directionality defect and/or Multiple pseudopods 12
Total number 386
Other Supporting Information Files
Dataset S1 (XLS)
Dataset S2 (XLS)
Dataset S3 (XLS)
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Supplemental Table 2.  Drugs that do not afftect neutrophil chemotaxis.  The movie files for each compound will be released to a public database after the publication of this paper.  
Tag No. Cat No. Drug Name Target Concentration used
1A2 0355 (+/-)-Acetylcarnitine chloride Intermediate in lipid metabolism 2.5mM
1H2 0384 N-Acetyl-L-leucyl-L-leucyl-L-methional Cathepsin inhibitor 1µM
1A3 0385 SG 209 K+ channel opener 2.88mM
1C3 0414 AG 490 EGFR-kinase inhibitor. Also JAK2, JAK3 inhibitor 135µM
1D3 0415 Ro 20-1724 PDE4 inhibitor 38µM
1 E3 0416 YS-035 hydrochloride Inhibits K+ outward / pacemaker current 300µM
1H3 0432 MY-5445 PDE5 inhibitor 5µM
1A4 0433 SC-9 Protein kinase C activator 5µM
1B4 0438 Etazolate hydrochloride PDE4 inhibitor 20µM
1C4 0442 4-Chlorophenylguanidine hydrochloride Urokinase inhibitor 60µM
1D4 0448 Calpeptin Calpain and cathepsin L inhibitor 520nM
1 E4 0455 (S)-(-)-Carbidopa Aromatic L-amino acid decarboxylase inhibitor 160µM
1F4 0462 (E)-Capsaicin Cis isomer of E-Capsaicin 3µM
1G4 0463 (Z)-Capsaicin Cis isomer of E-Capsaicin 3µM
1A5 0468 N1,N11-Diethylnorspermine tetrahydrochloride Spermine and spermidine acetyltransferase potentiator 100µM
1C5 0477 (+/-)-Decanoylcarnitine chloride Intermediate in lipid metabolism 2.5mM
1D5 0478 Flurofamide Urease inhibitor 5µM
1 E5 0483 OR-486 Catechol-O-methyl transferase inhibitor 370nM
1F5 0485 Alrestatin Aldehyde reductase/Aldose reductase inhibitor 580µM
1G5 0493 AG 18 EGFR/PDGFR-kinase inhibitor 350µM
1H5 0497 AG 99 EGFR kinase inhibitor 100µM
1A6 0500 N(1),N(12)-Diethylspermine tetrahydrochloride Polyamine synthase inhibitor 100µM
1B6 0503 AG 213 EGFR/PDGFR-kinase inhibitor 30µM
1D6 0507 Dantrolene sodium salt Ca2+ release inhibitor 100µM
1 E6 0512 SKF 91488 dihydrochloride Histamine N-methyl transferase inhibitor 10µM
1F6 0518 EBPC Aldose reductase inhibitor 470nM
1H6 0526 (+/-)-Hexanoylcarnitine chloride Intermediate in lipid metabolism 2.5mM
1D7 0546 L-NIO dihydrochloride Potent eNOS inhibitor 5µM
1F7 0552 MMPX PDE1 inhibitor 52µM
1H7 0571 PCA 4248 PAF receptor antagonist 10.5µM
1A8 0577 Methyl 2,5-dihydroxycinnamate EGFR-kinase inhibitor 7.7µM
1B8 0578 Tyrphostin B44 EGFR-kinase inhibitor 4µM
1C8 0579 Tyrphostin B44 (+) EGFR-kinase inhibitor 8.6µM
1D8 0583 Minoxidil K+ channel (KATP) opener 1.4µM
1 E8 0584 L(-)-alpha-Methyldopa Aromatic L-amino acid decarboxylase inhibitor 100µM
1F8 0593 NPPB Chloride channel blocker 800nM
1G8 0598 SNAP A stable analogue of endogenous S-nitroso compounds 50µM
1B9 0602 7-Nitroindazole Non-selective NOS inhibitor. 4.7µ
1C9 0603 SNOG NO carrier. Breaks down to release NO 200µM
1D9 0605 (+/-)-Octanoylcarnitine chloride Intermediate in lipid metabolism 500µM
1 E9 0606 OBAA Phospholipase A2 700nM
1F9 0607 17-ODYA LTB-omega-Hydroxylase inhibitor 400µM
1H9 0611 (+/-)-Propionylcarnitine chloride Intermediate in lipid metabolism 500µM
1A10 0615 trans-4-Phenylchalcone oxide Potent and selective inhibitor of trans-styrene oxide hydrolase 640nM
1B10 0616 AG 556 EGFR-kinase inhibitor 11µM
1C10 0618 AG 555 Potent EGFR-kinase inhibitor 7µM
1D10 0619 AG 494 Potent EGFR-kinase inhibitor 7µM
1 E10 0630 Rosmarinic acid Antiinflammatory, cytostatic, and antiviral 1.8mM
1G10 0645 2-(1-Thienyl)ethyl 3,4-dihydroxybenzylidenecyanoacetate 5-, 12-, 15-Lipoxygenase 5µM
1H10 0650 Trimethoprim Dihydrofolate reductase inhibitor 140µM
1A11 0652 Thalidomide TNF-alpha synthesis inhibitor 155µM
1C11 0663 L-Arginine Endogenous substrate for NOS 100µM
1D11 0664 L-NNA NOS inhibitor (nNOS = eNOS >>iNOS) 30µM
1 E11 0665 L-NAME hydrochloride Non-selective NOS inhibitor (muscarinic acetylcholine receptor antagonist) 1mM 
1F11 0671 AH 6809 EP1 and EP2 receptor antagonist 3.5µM
1G11 0673 L-Canavanine sulfate iNOS inhibitor 1mM
1H11 0674 Dequalinium dichloride K+ channel blocker (SKCa) 11µM
2B2 0681 L-690,330 Inositol monophosphatase inhibitor 3µM
2D2 0687 Danazol Anterior pituitary suppressant 1.16µM
2 E2 0695 Retinoic acid Keratolytic 100µM
2F2 0708 Hydroxypropyl-beta-cyclodextrin Widely used cyclodextrin 5mM 
2G2 0710 6-Nitroindazole nNOS inhibitor. 2.4mM
2H2 0722 N-Acetyl-N-acetoxy-4-chlorobenzenesulfonamide Nitroxyl precursor 11.5µM
2A3 0723 Tetrindole mesylate MAO-A 4µM
2B3 0724 Pirlindole mesylate MAO-A 5µM
2C3 0727 Pyrrolidinedithiocarbamate Ammonium Inhibits NFkappaB, prevents increase in NOS mRNA 410µM
2D3 0735 3-Bromo-7-nitroindazole Selective nNOS inhibitor 8.6µM
2G3 0746 Zinc protoporphyrin IX Haem oxygenase and guanylyl cyclase inhibitor 500nM
2H3 0747 Tin protoporphyrin IX dichloride Haem oxygenase inhibitor 100µM
2B4 0756 SIN-1 chloride Water soluble NO donor 1mM
2D4 0759 Castanospermine Glucosidases alpha and beta 100µM
2 E4 0760 AM 580 Retinoic acid agonist 3.4nM
2F4 0761 TTNPB Retinoic acid agonist 100nM
2H4 0771 L-NMMA Non-selective NOS inhibitor 70µM
2A5 0772 Carboxy PTIO potassium salt Stable, water soluble deactivator of NO 300µM
2B5 0776 (S)-Methylisothiourea sulfate Highly selective iNOS inhibitor 60µM
2C5 0786 MCI-186 Anti-ischaemic agent, and antioxidant 300µM
2D5 0787 Aminoguanidine hydrochloride Irreversible iNOS inhibitor 1.5mM
2 E5 0788 3-Aminobenzamide PARP inhibitor 400µM
2F5 0800 7-NINA Water soluble sodium salt of (0602) 1mM
2G5 0825 Clofibric acid PPAR agonist 12µM
2H5 0836 ICI 185,282 Potent thromboxane receptor antagonist 1µM
2A6 0837 ICI 192,605 Potent thromboxane A2 / TP receptor antagonist 1µM
2B6 0839 DHBP dibromide Ca2+ release inhibitor(interaction with ryanodine receptor) 48.6µM
2C6 0847 Statil Aldose reductase inhibitor 23µM
2D6 0871 AMT hydrochloride Potent, selective iNOS inhibitor (isoform II selective) 36nM
2 E6 0873 EIT hydrobromide Selective iNOS inhibitor, acts arginine binding site (isoform II selective) 130nM
2F6 0876 AM 92016 hydrochloride K+ channel blocker (KV) 300nM
2G6 0880 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one Selective inhibitor of NO-sensitive guanylyl cyclase 200nM
2H6 0882 ZM 226600 KATP channel opener 5µM
2A7 0897 S-Isopropylisothiourea hydrobromide iNOS inhibitor, acts arginine binding site 98nM
2B7 0905 (S)-(-)-Rolipram Less active enantiomer of (0905), PDE4 inhibitor 20µM
2D7 0915 Cilostamide PDE3 inhibitor(PDE3A/PDE3B) 570nM
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2 E7 0919 TRIM nNOS / iNOS inhibitor 270µM
2F7 0934 Olvanil Potent vanilloid receptor agonist/anandamide uptake blocker 90µM
2G7 0940 4-Aminopyridine K+ channel blocker 100µM
2H7 0942 NS 398 Selective Cox-2 inhibitor 38µM
2A8 0947 Zaprinast PDE5/6/9/11 inhibitor 120µM
2B8 0951 2-Iminopiperidine hydrochloride Selective iNOS inhibitor 100µM
2C8 0960 Piroxicam Cyclooxygenase (COX-1) inhibitor 300µM
2D8 0963 9-AC Chloride transport inhibitor 1mM
2 E8 0970 Cycloheximide Inhibitor of protein synthesis 50µM
2G8 1000 ZD 7288 Sino-atrial node function modulator (If inhibitor) 3µM
2H8 1014 QX 314 Na+ channel blocker 24µM
2A9 1037 PD 153035 hydrochloride EGFR kinase inhibitor 290pM
2B9 1041 1-EBIO Activator of epithelial KCa channels 4.9mM
2C9 1042 N-Methyllidocaine iodide Enhances biosynthesis of phosphatidylinositol 1.3mM
2D9 1043 QX 222 Na+ channel blocker 280µM
2 E9 1046 Zardaverine PDE3/4 inhibitor 8µM
2F9 1047 ICI 182,780 Oestrogen receptor antagonist 2.9nM
2G9 1075 Nifedipine Ca2+ channel blocker (L-type) 35nM
2H9 1076 Ouabain Na+,K+-ATPase 30nM
2A10 1089 8-Bromo-cGMP, sodium salt cGMP analogue 1µM
2B10 1093 Pirfenidone Antifibrotic agent 5mM 
2C10 1095 (R)-(-)-Deprenyl hydrochloride MAO-B inhibitor 100µM
2D10 1097 Taxol Promotes assembly and inhibits disassembly of microtubules 10nM
2F10 1099 Forskolin Adenylyl cyclase activator 100µM
2G10 1100 Camptothecin DNA topoisomerase (TOPI) 255µM
2H10 1101 Cyclosporin A Calcineurin inhibitor 50nM
2A11 1103 Ketoconazole Cytochrome P450c17 inhibitor 12.3µM
2B11 1110 Genistein EGFR-kinase, topoisomerase kinase inhibitor 25µM
2C11 1114 CGP 37157 Antagonist of mitochondrial Na+/Ca2+ exchange 4µM
2D11 1125 Quercetin Non-selective PI 3-kinase inhibitor 110µM
2 E11 1126 Dexamethasone Anti-inflammatory glucocorticoid 100nM
2F11 1130 LY 294002 hydrochloride Selective PI 3-kinase inhibitor 14µM
2G11 1135 Spermine NONOate Slow NO releasing agent 62µM
2H11 1139 L-NIL hydrochloride Selective iNOS inhibitor 33µM
3A2 1140 8-Bromo-cAMP, sodium salt Cell-permeable cAMP analogue 1mM
3C2 1144 U0126 Potent, selective inhibitor of MEK1 and 2 700nM
3 E2 1148 Siguazodan PDE3 inhibitor 1.17µM
3F2 1200 N(omega)-Propyl-L-arginine Highly selective inhibitor of nNOS 570nM
3G2 1202 SB 203580 Selective inhibitor of p38 MAPK(SAPK2a/p38, SAPK2b/p38b2) 5µM
3H2 1206 SC 19220 Selective EP1 receptor antagonist 67µM
3B3 1222 DMPQ dihydrochloride Potent inhibitor of beta-type PDGFRTK 800nM
3D3 1226 Etoposide Topoisomerase II inhibitor 592µM
3G3 1229 Actinomycin D Antineoplastic antibiotic (inhibit RNA synthesis) 76nM
3H3 1230 Methotrexate Cytotoxic agent (inhibit DNA synthesis) 100nM
3A4 1231 Brefeldin A Disrupts protein translocation to Golgi 2µM
3B4 1232 Wortmannin Potent, irreversible inhibitor of PI 3-kinase 24nM
3C4 1233 Cytochalasin D Disrupts actin filament function 20nM
3 E4 1235 Cyclopiazonic acid Inhibitor of SERCA ATPase 8µM
3F4 1236 BHQ Inhibitor of SERCA ATPase 10µM
3G4 1244 KB-R7943 mesylate Na+/Ca2+ exchange inhibitor 7µM
3A5 1257 Vincristine sulfate Disrupts microtubules 850nM
3B5 1258 1-Deoxynojirimycin Glucosidase I and II inhibitor 70µM
3C5 1259 1-Deoxymannojirimycin hydrochloride alpha-Mannosidase I inhibitor 60µM
3 E5 1264 SB 202190 Potent, selective inhibitor of p38 MAPK (p38alpha/p38beta) 1µM
3F5 1267 Pifithrin-a hydrobromide P53 inhibitor 100µM
3H5 1276 AG 1478 hydrochloride Highly potent EGFR kinase inhibitor 30nM
3A6 1283 ARL 67156 Ecto-ATPase 1mM
3B6 1284 Olomoucine Cyclin-dependent kinase inhibitor 70µM
3C6 1290 Anisomycin Protein synthesis inhibitor (block translation) 10µM
3D6 1300 LFM-A13 Potent, selective BTK inhibitor 25µM
3 E6 1304 BW-B 70C 5-Lipoxygenase inhibitor 300µM
3F6 1305 Monastrol Selective inhibitor of mitotic kinesin Eg5 140µM
3G6 1307 Ciglitazone Selective PPARgamma agonist 30µM
3H6 1310 UCL 1684 Non-peptidic blocker of the apamin-sensitive Ca2+-activated K+ channel. 7.62nM
3A7 1311 MK 886 Inhibitor of 5-lipoxygenase-activating protein 300nM
3B7 1312 WY 14643 Selective PPARalpha agonist 6.3µM
3C7 1321 ZM 336372 Potent, selective c-Raf inhibitor 700nM
3D7 1323 Butabindide oxalate CCK-inactivating serine peptidase inhibitor 70nM
3 E7 1326 BADGE PPAR gamma antagonist 55µM
3F7 1349 (R)-(-)-Rolipram (-)? More active enantiomer of (0905) 24nM
3G7 1350 (S)-(-)-Rolipram (+)? Less active enantiomer of (0905) 500nM
3H7 1355 P1075 Potent KATP channel opener 75nM
3B8 1367 ZM 39923 Potent, selective Jak3 inhibitor 794nM
3C8 1377 Cromakalim KATP channel opener. Active enantiomer of (1377) 210nM
3D8 1378 Levcromakalim KATP channel opener. Active enantiomer of (1377) 4.9µM
3 E8 1381 GW 5074 Potent, selective cRaf1 kinase inhibitor 90nM
3F8 1397 PP 1 Potent, selective Src inhibitor 60nM
3G8 1398 Kenpaullone Potent cyclin-dependent kinase inhibitor(CDK1/cyclinB, GSK-3beta) 4µM
3H8 1399 CP 339818 hydrochloride Non-peptide, potent Kv1.3 channel blocker(Kv1.3, Kv1.4) 3µM
3A9 1400 SCH 202676 hydrobromide Allosteric inhibitor of ligand binding to G protein-coupled receptors 18µM
3B9 1401 NU 1025 Potent PARP inhibitor 4µM
3C9 1402 SB 203580 hydrochloride Water soluble salt of (1202) (SAPK2a/p38, SAPK2b/p38beta2) 5µM
3D9 1403 FPL 64176 Potent activator of L-type Ca2+ channels 160nM
3F9 1407 PP 2 Potent, selective Src inhibitor 50nM
3G9 1412 (-)-[3R,4S]-Chromanol 293B IKs blocker. Enantiomer of (1412) and Icftr (CFTR chloride current) blocker 190µM
3H9 1415 1400W dihydrochloride Potent, highly selective iNOS inhibitor 70nM
3A10 1416 Homoharringtonine Inhibitor of protein synthesis. Antileukemic 9.2µM
3B10 1417 Daidzein Arrests cell cycle in G1 phase. 78.6µM
3C10 1418 Resveratrol Anti-tumour and anti-oxidant agent 230µM
3 E10 1426 PPT Subtype selective ERa agonist 2nM
3F10 1430 DuP 697 Cyclooxygenase (COX-2) inhibitor 100nM
3H10 1439 Ruthenium Red Blocks Ca2+ release from mitrochondia and intracellular stores 1µM
3A11 1442 BMY 45778 Non-prostanoid prostacyclin IP receptor partial agonist. 350nM
3B11 1459 SU 4312 Potent inhibitor of VEGFR tyrosine kinase/PDGFR tyrosine kinase 8µM
3D11 1461 Linomide Immunomodulator with antitumour properties. 300µM
3 E11 1467 Daunorubicin hydrochloride Anticancer agent 50µM
3F11 1470 Flecainide acetate Cardiac Na+ channel blocker. Antiarrhythmic(stimulated/resting) 410µM
3G11 1475 (-)-[3R,4S]-Chromanol 293B IKs blocker. Enantiomer of (1412) 13.6µM
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3H11 1479 Mifepristone Progesterone and glucocorticoid antagonist 50µM
4A2 1494 DPN Highly potent ERbeta agonist 8.5nM
4B2 1496 SP 600125 Novel and selective JNK inhibitor 900nM
4C2 1503 Pinacidil K+ channel opener. Activates KATP Channels 12.6µM
4D2 1504 Milrinone PDE3 inhibitor 560nM
4 E2 1505 Mycophenolic acid Immunosuppresant 1µM
4F2 1507 FR 122047 Cyclooxygenase (COX-1) inhibitor 280nM
4G2 1508 GW 9662 Selective PPARgamma antagonist 33nM
4H2 1509 TMS Cytochrome P450 1B1 inhibitor 60nM
4A3 1510 Ozagrel hydrochloride Selective thromboxane A2 synthetase inhibitor 40nM
4B3 1526 Mevastatin HMG-CoA reductase inhibitor 1µM
4C3 1530 Lovastatin Potent, competitive inhibitor of HMG-CoA 6nM
4D3 1531 Icilin Activates a novel cold receptor. Cooling agent 3.6µM
4H3 1544 (±)-Bay K 8644 Ca2+-channel activator (L-type) 173nM
4A4 1546 (S)-(-)-Bay K 8644 Ca2+-channel activator (L-type) 100nM
4B4 1547 NSC 95397 Selective Cdc25 dual specificity phosphatase inhibitor against Cdc25A,-B,-C 960nM
4 E4 1555 AG 825 EGFR-kinase inhibitor, selective for Her2 1.5µM
4F4 1580 Purvalanol A Cyclin-dependent kinase inhibitor(cdc2/cyclinB, cdk2/cyclinA, cdk2/cyclinE, cdk4/cyclinD1, cdk5-p35) 8.5µM
4G4 1581 Purvalanol B Cyclin-dependent kinase inhibitor(cdc2/cyclinB, cdk2/cyclinA, cdk2/cyclinE, cdk5-p35) 90nM
4H4 1603 NKH 477 Water-soluble adenylyl cyclase activator 326nM
4B5 1614 SB 431542 Potent and selective inhibitor of TGF-beta type 1 receptor activin receptor-like kinase ALK5 940nM
4C5 1615 SB 366791 Potent, selective, competitive VR1 antagonist 6.519µM
4D5 1616 SB 216763 Potent selective GSK-3 inhibitor (alpha) 90nM
4 E5 1617 SB 415286 Potent selective GSK-3 inhibitor (alpha) 310nM
4F5 1620 Alprostadil Prostaglandin. Vasodilator and anti-platelet agent in vivo (EP3&EP4 receptors blocker) 21nM
4G5 1621 Streptozocin DNA alkylator; antitumour and induces diabetes 100µM
4A6 1634 Y 29794 oxalate Prolyl endopeptidase inhibitor 9.5nM
4B6 1638 U 18666A Inhibitor of hedgehog (hh) signalling. Also inhibits cholesterol synthesis 320nM
4F6 1657 Ginkgolide B PAF receptor antagonist 13µM
4G6 1664 GW 1929 Selective PPARg agonist. Orally active 89nM
4H6 1672 RU 28318, potassium salt Potent, selective mineralocorticoid receptor antagonist 1mM
4B7 1676 T 0156 hydrochloride Highly potent, selective PDE5 inhibitor 2.3nM
4C7 1677 GW 7647 Highly selective, potent PPARa agonist. Orally active 60nM
4D7 1690 SCH 28080 H+,K+-ATPase inhibitor 200nM
4 E7 1692 Cilostazol PDE3A inhibitor. Also adenosine uptake inhibitor 2µM
4F7 1694 Ibudilast PDE inhibitor (non-selective)(Ia, II, III, IV, V) 480µM
4G7 1697 Noscapine hydrochloride Tubulin inhibitor; induces apoptosis (inhibit stimulated PI turnover) 100µM
4H7 1698 L-655,240 Potent, selective thromboxane A2/prostaglandin endoperoxide antagonist 70nM
4A8 1706 Acetaminophen Cyclooxygenase (COX-3) inhibitor 4.6mM
4C8 1708 Indomethacin Cyclooxygenase inhibitor (COX-1 > COX-2) 6.3µM
4F8 1748 MG 132 Inhibits NF-kB activation; proteasome and calpain inhibitor. 12µM
4G8 1758 PETCM Activator of caspase-3 200µM
4H8 1759 Nilutamide Androgen receptor antagonist. Orally active 5µM
4B9 1761 Baicalein 5- and 12-Lipoxygenase inhibitor 95µM
4C9 1762 Acifran Hypolipidemic agent; agonist for the HM74A receptor 21µM
4D9 1769 Flurbiprofen Cyclooxygenase inhibitor(COX-1 and COX-2) 4µM
4 E9 1770 Deguelin Anticancer and antiviral agent 110nM
4F9 1777 Arctigenin Inhibitor of IkBa phosphorylation 100nM
4H9 1794 Ro 26-4550 trifluoroacetate Competitive reversible inhibitor of interleukin-2 (IL-2) binding to its receptor 30µM
4A10 1804 SR 2640 hydrochloride Potent, selective LTD4 /LTE4 receptor antagonist 230nM
4B10 1806 SR 33805 oxalate Ca2+ channel blocker; binds allosterically to distinct site on L-type channels 8.9nM
4D10 1808 E-4031 dihydrochloride Selective blocker of HERG K+ channels 78µM
4 E10 1813 Indirubin-3'-oxime GSK-3b inhibitor 1.9µM
4F10 1816 ICI 63197 PDE4 inhibitor 350nM
4G10 1819 Demethylasterriquinone B1 Selective insulin RTK activator 60µM
4H10 1821 YM 976 Orally active PDE4 inhibitor. 22nM
4A11 1850 EXO 1 Reversible inhibitor of vasicular trafficking between endoplasmic reticulum and Golgi apparatus 200µM
4C11 1856 L-165,041 Potent PPARd agonist 60nM
4D11 1862 PRIMA-1 Restores mutant p53 activity; induces apoptosis 20µM
4 E11 1866 MRS 1845 Potent SOC inhibitor; blocks intracellular Ca2+ release 17µM
4H11 1937 NSC 693868 Cdk inhibitor. Also inhibits GSK-3(cdk1/cyclinB, cdk5/p25, GSK-3) 10µM
5B2 1942 o-3M3FBS Inactive analogue of m-3M3FBS 100µM
5C2 1949 L-670,596 Potent and selective thromboxane A2/prostaglandin endoperoxide receptor antagonist 55nM
5D2 1956 Bestatin Aminopeptidase inhibitor 1.62µM
5 E2 1958 GR 32191 hydrochloride Potent thromboxane A2/TP receptor antagonist 3µM
5F2 1959 GW 311616 hydrochloride Potent and selective inhibitor of human neutrophil elastase. 220nM
5G2 1962 SB 239063 Potent, selective p38 MAP kinase inhibitor; orally active 440nM
5A3 1965 Simvastatin HMG-CoA reductase inhibitor 10µM
5B3 1969 SL 327 Selective inhibitor of MEK1 and MEK2  2.2µM
5C3 1975 6-Iodonordihydrocapsaicin Potent, competitive vanilloid receptor antagonist 100nM
5D3 1991 MPP dihydrochloride Highly selective ERa antagonist 27nM
5F3 2000 XE 991 dihydrochloride Potent and selective blocker of KCNQ voltage-gated potassium channels 9.8µM
5H3 2004 Isradipine Potent and selective L-type voltage-gated Ca2+ channel blocker 14nM
5A4 2006 Paxilline Potent blocker of high-conductance Ca2+-activated K+ channels 19nM
5B4 2007 Fluticasone propionate High affinity, selective glucocorticoid receptor agonist 37nM
5C4 2008 SKF 86002 dihydrochloride Inhibitor of p38 MAP kinase 10µM
5D4 2020 Ch 55 Highly potent synthetic retinoid that has high affinity for RAR-a and RAR-b receptors 10nM
5F4 2022 SR 202 Selective PPARg antagonist; antidiabetic and antiobesity agent 1.4mM
5G4 2025 Cinalukast Potent, selective CysLT1 (LTD4) leukotriene receptor antagonist 64nM
5H4 2072 Aminopurvalanol A Cell-permeable cyclin-dependent kinase inhibitor 330nM 
5A5 2076 Y-26763 KATP channel opener and active metabolite of Y-27152 270nM
5B5 2077 Y-27152 Prodrug of the KATP channel opener Y-26763 1µM
5C5 2088 DMNB Inhibitor of DNA-dependent protein kinase (DNA-PK) 150µM
5 E5 2095 PNU 37883 hydrochloride Novel antagonist selective for the vascular form of KATP channel 6.5nM
5F5 2097 SKI II Selective non-lipid inhibitor of sphingosine kinase 5µM
5H5 2137 2,3-DCPE hydrochloride Selective induces apoptosis and down-regulates Bcl-XL protein expression 126µM
5A6 2140 LY 171883 Selective, orally active leukotriene D4 (LTD4) antagonist 6.3µM
5B6 2147 Nicorandil KATP channel opener and NO donor 100µM
5C6 2150 nTZDpa Potent, selective non-thiazolidinedione PPARg partial agonist 2.85µM
5 E6 2152 NSC 625987 CDK-4(cdk4/cyclinD1) inhibitor 2µM
5A7 2172 AZ 10417808 Selective non-peptide inhibitor of caspase-3  149µM
5C7 2183 ZK 164015 Potent estrogen receptor silent antagonist 250nM
5D7 2184 SN-6 Selective Na+/Ca2+-exchange (NCX) inhibitor 160µM
5F7 2186 CMPD-1 Non-ATP-competitive, selective inhibitor of p38a-mediated MK2a phosphorylation 3.3µM
5G7 2192 4-HQN Inhibitor of poly(ADP-ribose) polymerase (PARP) 95µM
5A8 2202 Zatebradine hydrochloride Bradycardic agent that produces use-dependent inhibition of hyperpolarisation-activated current (If) 4.8µM
5B8 2208 LY 255283 Selective, competitive antagonist of BLT2 receptors 10µM
5C8 2227 CI 976 Selective acyl-coenzyme A:cholesterol acyltransferase (ACAT) inhibitor 730nM
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5 E8 2229 GW 0742 Potent and highly selective PPARd agonist 10nM
5F8 2239 GW 583340 dihydrochloride Potent dual EGFR/ErbB-2 tyrosine kinase inhibitor 1.1µM
5G8 2251 Cisplatin Potent anticancer agent that blocks DNA synthesis 100µM
5H8 2252 Doxorubicin hydrochloride Antitumour antibiotic agent that inhibits DNA topoisomerase II 26.1µM
5A9 2266 DY131 Novel selective agonist at estrogen-related receptors ERRb and ERRg 30µM
5B9 2271 GW 6471 PPARa antagonist that inhibits activation 2.4µM
5C9 2275 TBB A cell-permeable selective inhibitor of casein kinase-2 (CK2) 16µM
5D9 2280 Raloxifene hydrochloride Selective estrogen receptor modulator (SERM) that binds to ERa and Erb 10nM
5 E9 2294 Cordycepin Nucleoside analogue that acts as an anticancer and antifungal agent 320µM
5F9 2301 T 0070907 Potent and selective PPARg antagonist 10nM
5G9 2313 QX 314 chloride Membrane impermeable blocker of voltage-activated Na+ channels 500µM
5H9 2318 Pravastatin sodium salt Water-soluble, competitive inhibitor of 3-hydroxy-3-methyl coenzyme A reductase 10nM
5A10 2324 Necrostatin-1 Blocks non-apoptotic cell death via inhibition of a specific cellular pathway 4.94µM
5B10 2330 DMP 543 K+ channel blocker and acetylcholine release stimulator 7µM
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Tag No. Drug Name Drug Target IC50 phenotype (10xIC50) phenotype (5xIC50) phenotype (2xIC50) phenotype (1xIC50) phenotype (0.5xIC50) phenotype (0.2xIC50)
1 E7 (+/-)-Lauroylcarnitine chloride Intermediate in lipid metabolism 250µM cell death cell death partially inhibited partially inhibited partially inhibited partially inhibited
1G7 (+/-)-Myristoylcarnitine chloride Intermediate in lipid metabolism 250µM cell death cell death cell death cell death slow migration no effect
1G9 (+/-)-Palmitoylcarnitine chloride Protein kinase C inhibitor 30µM cell death cell death cell death no effect no effect no effect
1B11 Verapamil hydrochloride Ca2+ channel blocker (L-type) 62µM cell death cell death no effect no effect no effect no effect
2C2 Diltiazem hydrochloride Ca2+ channel blocker (L-type) 320µM cell death cell death cell death no effect no effect no effect
2C7 Glibenclamide K+ channel blocker (KATP)/CFTR Cl- channel blocker 20µM cell death completely inhibited partially inhibited no effect no effect no effect
2F8 Tamoxifen citrate Oestrogen receptor partial agonist / antagonist 8µM cell death cell death slow & long-tailed no effect no effect no effect
2 E10 Tranilast Anti-allergic, inhibits release from mast cells(anti-AT1 receptor?) 100µM cell death no effect no effect no effect no effect no effect
3D4 A23187 Calcium ionophore 1.9µM cell death cell death cell death cell death cell death cell death
3C11 PACOCF3 Phospholipase A2 inhibitor 3.8µM cell death cell death no effect no effect no effect no effect
4G3 Splitomicin Histone deacetylase (Sir2p) inhibitor 60µM cell death no effect no effect no effect no effect no effect
4C6 AY 9944 dihydrochloride Inhibitor of hedgehog (hh) signaling. Inhibits D7-dehydrocholesterol reductase 210µM cell death cell death cell death completely inhibited no effect no effect
5A2 m-3M3FBS Phospholipase C activator 10µM cell death no effect no effect no effect no effect no effect
5F6 Embelin Cell-permeable inhibitor of X-linked inhibitor of apoptosis (XIAP) 4.1µM cell death cell death no effect no effect no effect no effect
5D8 Leflunomide Immunosuppressant agent. 100µM cell death cell death cell death no effect no effect no effectSupplemental Table 4.  Drugs that affect neutrophil chemotaxis .  The movie files for each compound will be released to a public database after the publication of this paper. 
Drugs that lead to slow and/or “long-tailed” migration (38 drugs)
Tag No. Drug Name Drug Target IC50 Phenotype (10xIC50) Phenotype (5xIC50) Phenotype (2xIC50) Phenotype (1xIC50) Phenotype (0.5xIC50)
1B2 W-13 hydrochloride Calmodulin antagonist 68µM cell death cell death completely inhibited very slow migration very slow migration
1C2 A-3 hydrochloride Protein kinase inhibitor 135µM cell death cell death cell death completely inhibited very slow migration
1 E2 W-7 hydrochloride Calmodulin antagonist 51µM cell death cell death completely inhibited completely inhibited very slow migration
1G2 A-7 hydrochloride Calmodulin antagonist 3µM completely inhibited completely inhibited slow migration slow migration   no effect
1B3 H-9 dihydrochloride Protein kinase inhibitor 70µM slow migration slow & long-tailed slow & long-tailed slow migration   partially inhibited
1G3 ML 9 hydrochloride Myosin light chain kinase inhibitor 4µM completely inhibited slow migration slow migration no effect no effect
1G6 Flunarizine dihydrochloride Dual Na+ / Ca2+ channel (T-type) blocker 4µM slow & long-tailed no effect no effect no effect no effect
1A7 Fasudil hydrochloride Inhibitor of cyclic nucleotide dependent protein kinases 10.7µM slow & long-tailed slow & long-tailed slow & long-tailed slightly long-tailed no effect
1B7 H-7 dihydrochloride Protein kinase inhibitor (PKC, PKG, PKA, MLCK) 6µM long-tailed migration long-tailed migration no effect no effect no effect
1C7 C-1 Protein kinase C inhibitor 64µM completely inhibited slow migration slow & long-tailed slow & long-tailed slow & long-tailed
1F10 D-erythro-Sphingosine Protein kinase C inhibitor 1.1µM slow migration no effect no effect no effect no effect
2F3 Ceramide Ser / Thr protein phosphatase activator 6µM completely inhibited slow migration slow migration no effect no effect
2A4 Dihydrosphingosine Protein kinase C inhibitor 2µM slow migration slow migration no effect no effect no effect
2C4 Vinpocetine Phosphodiesterase(PDE1) inhibitor/Na+ channel blocker 21µM slow migration slow migration no effect no effect no effect
3A3 PD 98059 Specific inhibitor of MEK 7µM slightly long tailed slightly long-tailed no effect no effect no effect
3C3 2APB Membrane permeable IP3 receptor antagonist 42µM very slow migration slow & long-tailed long-tailed no effect no effect
3 E3 Apigenin Anticancer agent 20µM slow & long-tailed slow & long-tailed slow & long-tailed long-tailed slightly long-tailed
3 E9 (-)-Terreic acid Selective inhibitor of BTK(Bruton's tyrosine kinase) 30µM slow migration no effect no effect no effect no effect
3D10 DCEBIO Activates Cl- conductance and hIK1 K+ channels 60µM partially inhibited long-tailed long-tailed long-tailed  no effect
4C4 Cantharidin Protein phosphatase 1 and 2A inhibitor 1.1µM slow migration slow migration no effect no effect no effect
4D4 STO-609 acetate Selective CaM kinase kinase inhibitor (CaM-KK alpha&beta) 214µM slow & long-tailed long-tailed long-tailed slightly long-tailed slightly long-tailed
4A7 YM 90709 Interleukin-5 receptor antagonist 1µM slow & long-tailed long-tailed no effect no effect no effect
4B8 Sulindac Cyclooxygenase inhibitor (following metabolism to sulindac sulfide) 100µM completely inhibited completely inhibited very slow migration slow & long-tailed slow migration
4A9 (±)-Blebbistatin Selective inhibitor of nonmuscle myosin II 2µM slow & long-tailed slow & long-tailed no effect no effect no effect
4G9 Ro 106-9920 Inhibitor of NF-kB activation 3µM completely inhibited very slow migration slow migration slightly slow no effect
4B11 (S)-(-)-Blebbistatin Selective inhibitor of nonmuscle myosin II ATPase activity 2µM slow & long-tailed slow & long-tailed slow & long-tailed long-tailed no effect
4F11 NSC 663284 Potent, selective inhibitor of Cdc25 dual specificity phosphatases 10µM very slow migration very slow migration very slow migration very slow migration slow & long-tailed
4G11 BTS Selective inhibitor of skeletal muscle myosin II ATPase activity 5µM slow migration slightly slow  no effect no effect no effect
5 E3 Linopirdine dihydrochloride Blocker of KCNQ voltage-gated potassium channels.(KCNQ1, KCNQ2+3) 8.9µM slow migration no effect no effect no effect no effect
5G3 Ro 31-8220 mesylate Protein kinase C inhibitor, with activity at other protein kinases 38nM slow & long-tailed slow migration slower migration no effect no effect
5D6 API-2 Selective inhibitor of Akt (protein kinase B) signaling 46µM slow migration slow migration no effect no effect no effect
5G6 Bax channel blocker Potent inhibitor of Bax-mediated mitochondrial cytochrome c release 520nM slow & long-tailed slow & long-tailed no effect no effect no effect
5B7 BVT 948 Non-competitive, cell permeable inhibitor of protein tyrosine phosphatases 7.1µM slow at first slow at first slow at first no effect no effect
5 E7 NSC 146109 hydrochloride Cell-permeable antitumour agent that activates p53-dependent transcription 15.8µM cell death cell death cell death slow migration slow migration
5H7 R 59-022 Diacylglycerol kinase inhibitor 2.8µM slow migration slow migration no effect no effect no effect
3G10 D609 Selective PC-PLC inhibitor 75µM partially inhibited partially inhibited partially inhibited partially inhibited no effect
4 E3 DCPIB Potent, selective blocker of the volume-sensitive anion channel (VSAC) 4.1µM partially inhibited partially inhibited partially inhibited partially inhibited partially inhibited
5H6 INCA-6 Inhibitor of interaction between calcineurin and its substrate NFAT 800nM partially inhibited partially inhibited partially inhibited no effect no effect
Drugs that completely inhibit polarization and migration (18 drugs)
Tag No. Drug Name Drug Target IC50 Phenotype (10xIC50) Phenotype (5xIC50) Phenotype (2xIC50) Phenotype (1xIC50) Phenotype (0.5xIC50)
1D2 W-5 hydrochloride Calmodulin antagonist 240µM cell death cell death cell death completely inhibited completely inhibited
1F2 W-9 hydrochloride Calmodulin antagonist 72µM cell death cell death cell death completely inhibited completely inhibited
1F3 SC-10 Protein kinase C activator 100µM cell death completely inhibited completely inhibited completely inhibited no effect
1H4 Capsazepine Vanilloid receptor antagonist. 3.2µM completely inhibited partially inhibited no effect no effect no effect
1H8 Nimodipine Ca2+ channel blocker (L-type) 60µM cell death completely inhibited completely inhibited partially inhibited partially inhibited
1A9 Nitrendipine Ca2+ channel blocker (L-type) 30µM completely inhibited completely inhibited partially inhibited no effect no effect
2A2 NPC 15199 Novel anti-inflammatory agent 36µM completely inhibited completely inhibited completely inhibited no effect no effect
2G4 Bifemelane hydrochloride MAO-A and MAO-B inhibitor 30µM completely inhibited completely inhibited completely inhibited slow migration slow migration
3G5 U 73122 Phospholipase C inhibitor 5µM completely inhibited completely inhibited partially inhibited partially inhibited partially inhibited
4F3 HA14-1 Bcl-2 inhibitor. Induces apoptosis 9µM cell death completely inhibited completely inhibited partially inhibited partially inhibited
4A5 Rottlerin Reported PKCd inhibitor 6µM completely inhibited partially inhibited partially inhibited no effect no effect
4H5 NPC 15437 dihydrochloride Selective protein kinase C inhibitor 19µM cell death cell death completely inhibited partially inhibited slow migration
4 E6 Lonidamine Anticancer and antispermatogenic agent. Inhibits mitochondrial hexokinase 365µM completely inhibited completely inhibited completely inhibited partially inhibited no effect
4D8 Bay 11-7085 Irreversible inhibitor of TNF-a-induced IkBa phosphorylation 10µM completely inhibited completely inhibited completely inhibited completely inhibited slow migration
4 E8 Bay 11-7821 Irreversible inhibitor of TNF-a-induced IkBa phosphorylation 10µM completely inhibited completely inhibited completely inhibited completely inhibited slow migration
5H2 Gossypol Anticancer, antifertility agent 7µM completely inhibited partially inhibited no effect no effect no effect
5D5 RS 102895 hydrochloride CCR2b-selective chemokine receptor antagonist 17.8µM completely inhibited slow migration no effect no effect no effect
5G5 Apoptosis Activator 2 Apoptosis activator 9µM completely inhibited partially inhibited no effect no effect no effect
Drugs that lead to directionality defect and/or multiple pseudopods (12 drugs)
Tag No. Drug Name Drug Target IC50 Phenotype (10xIC50) Phenotype (5xIC50) Phenotype (2xIC50) Phenotype (1xIC50) Phenotype (0.5xIC50)
1B5 2,4-Diamino-6-hydroxypyrimidine Inhibits biosynthesis of tetrahydrobiopterin and thus NOS 300µM cell death completely inhibited partially inhibited random movement random movement
1C6 Diphenyleneiodonium chloride Binds to flavoproteins and inhibits NADPH oxidase 10µM multiple pseudopods multiple pseudopods multiple pseudopods multiple pseudopods no effect
2 E3 GF 109203X Protein kinase C inhibitor(α/β1/γ/δ/ε/ζ subtypes) 5.8µM completely inhibited head shaking  random movement multiple pseudopods no effect
3B2 Dibutyryl-cAMP, sodium salt Cell-permeable cAMP analogue 100µM head shaking slightly head shaking no effect no effect no effect
3D2 SKF 96365 hydrochloride Receptor-operated calcium channel blocker 11.2µM random movement random movement random movement no effect no effect
3F3 Nocodazole Microtubule inhibitor 3.2µM long-tailed multiple pseudopod multiple pseudopod random movement random movement
3H4 Vinblastine sulfate Disrupts microtubules 178nM slightly random slight random slightly random slightly random no effect
3D5 EHNA hydrochloride Adenosine deaminase inhibitor 4µM multiple pseudopods multiple pseudopods slow migration no effect no effect
3A8 Colchicine Inhibitor of tubulin 1µM random movement slightly random slightly random slightly random  slightly random
4D6 D-64131 Inhibitor of tubulin polymerization. Antitumour in vivo 74nM random movement slightly random no effect no effect no effect
4C10 2-Methoxyestradiol Apoptotic and antiangiogenic agent (inhibits tubulinpolymerization) 1.9µM random movement no effect no effect no effect no effect
5 E4 LE 135 Retinoic acid antagonist 1.4µM multiple pseudopods multiple pseudopods multiple pseudopods multiple pseudopods multiple pseudopods